Adverse Event reporting information can be found in footer

Request a Meeting
PI
Home A Different Class of ADT Control CV Risk Economic Burden of CVD Events Disease-Related Symptoms Delay Disease Progression Patient Satisfaction Support & Resources Dosing & Administration Firmagon Licence Prescribing Information
Firmagon degarelix. Think beyond the prostate Icon Icon Icon Icon

FIRMAGON® is an ADT in a Different Class1

FIRMAGON® is a GnRH antagonist, but how does this differ from an agonist?
Find out...

LHRH agonists overstimulate GnRH receptors, initially inducing an increase of LH, FSH and testosterone (which can lead to clinical flare) before causing suppression…

LHRH Agonist

…whereas GnRH antagonists like FIRMAGON® block GnRH receptors leading to immediate and profound suppression of LH, FSH and testosterone, and so achieve rapid symptom relief.

GnRH Antagonist Firmagon®

FIRMAGON® is associated with fewer systemic adverse events vs. LHRH agonists4,5



Adapted from Klotz L, et al. 20143

  • The most common adverse reactions for FIRMAGON® were those related to testosterone suppression, or injection site reactions (ISRs)4,5
  • ISRs were mostly transient, of mild to moderate intensity and led to very few discontinuations (<1%)5
arrow pointing down
Injection site reactions (ISRs) occurred mainly with the starting dose; but incidence dropped from 33% to 4% with maintenance injections5

Consult the SmPCs for full safety information2,3

*p<0.05. Treatment-emergent AEs occurring over 1 year with FIRMAGON® and LHRH agonists (>5% in any treatment group; pooled analysis of five prospective, randomised Phase III trials).
†LHRH agonists include goserelin and leuprorelin.

Watch How FIRMAGON®s MOA Works

up arrow dark up arrow down arrow dark down arrow
▲ SECTION NAVIGATION ▲

A Different Class

Fewer adverse events

MOA Video
References

References
1. Drudge-Coates L. Int J Urol Nurs 2009;3(3):85–92.
2. FIRMAGON® 120mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: https://www.medicines.org.uk/emc/product/6537. Last accessed: January 2024.
3. FIRMAGON® 80 mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: https://www.medicines.org.uk/emc/product/6535. Last accessed: January 2024.
4. Klotz L, et al. Eur Urol 2014;66:1101–1108.
5. Klotz L, et al. BJU Int 2008;102:1531-1538.

Job Code: UK-FN-2400002 - Date of Preparation: March 2024

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.